Presenting non-insulin-based indices of insulin resistance relevant to pre-hypertension: A systematic review and meta-analysis.

Clin Exp HypertensFeb 4, 2026 (epub)
Clinical ResearchCardiologyEndocrinology

Maryam Farahmand, Sima Nazarpour, Hanieh Malmir et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined associations between non-insulin-based insulin-resistance indices and pre-hypertension in studies using cross-sectional designs. Fifteen studies were included in the review and 14 in the meta-analysis. TyG, TyG-BMI, TyG-WC, TG/HDL-C, and METS-IR were each associated with significantly higher odds of pre-hypertension. The diagnostic odds ratio was 2.67 (95% CI: 2.39-2.97) for TyG and 3.45 (95% CI: 2.73-4.35) for TyG-BMI. The findings indicate association, not causation.

Key findings

  • All 15 included studies were cross-sectional or used a cross-sectional approach; 14 contributed to the meta-analysis.
  • TyG was associated with pre-hypertension, with a diagnostic odds ratio of 2.67 (95% CI: 2.39-2.97).
  • TyG-BMI was associated with pre-hypertension, with a diagnostic odds ratio of 3.45 (95% CI: 2.73-4.35).
  • TyG-WC, TG/HDL-C, and METS-IR were also associated with significantly increased odds of pre-hypertension (P < 0.05).

Why it matters

These findings suggest that routinely derived, non-insulin-based indices may help identify people with pre-hypertension and support earlier assessment of cardiovascular risk. However, the evidence is cross-sectional, so it cannot establish whether insulin resistance precedes pre-hypertension or causes it. Prospective research is needed before the indices’ predictive value or role in prevention can be established.

What to keep in mind

All included studies were cross-sectional or used a cross-sectional approach, preventing causal inference; the authors call for prospective and longitudinal research.

Source

Published in Clin Exp Hypertens. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.